SERPINA1 encodes alpha-1 antitrypsin (A1AT), a member of the serpin superfamily of serine protease inhibitors. While classically studied in the context of lung emphysema and liver disease due to deficiency states, emerging evidence positions SERPINA1 as a significant player in neurodegenerative disease pathogenesis. Alpha-1 antitrypsin functions as an acute-phase protein with broad anti-inflammatory properties, including inhibition of neutrophil elastase, cathepsin G, and proteinase-3. In the central nervous system, A1AT is produced by astrocytes and microglia, where it modulates neuroinflammation, oxidative stress, and proteostasis—all key processes in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) pathogenesis. [1]
| Property | Value |
|---|---|
| Gene Symbol | SERPINA1 |
| Gene Name | Serpin Family A Member 1 (Alpha-1 Antitrypsin) |
| Chromosomal Location | 14q32.13 |
| NCBI Gene ID | 5265 |
| OMIM | 107400 |
| UniProt | P01009 |
| Ensembl | ENSG00000197249 |
| RefSeq mRNA | NM_001002236 |
| Protein Length | 418 amino acids |
Alpha-1 antitrypsin is a 52 kDa glycoprotein synthesized primarily in the liver, with extrahepatic expression in astrocytes, microglia, and macrophages throughout the body. The protein possesses a characteristic serpin fold with a reactive center loop (RCL) that acts as a bait for target proteases. Upon proteolytic cleavage, A1AT undergoes a dramatic conformational change, forming a stable complex with the protease and rendering it inactive. [2]
The physiological functions of A1AT extend well beyond its canonical protease inhibitory activity:
Anti-inflammatory Effects: A1AT reduces cytokine production from activated microglia, limits neutrophil infiltration, and attenuates inflammasome activation. The protein exerts these effects partly through direct interaction with CD95/Fas receptor, promoting anti-apoptotic signaling. [3]
Antioxidant Properties: A1AT scavenges reactive oxygen species (ROS) and upregulates cellular antioxidant defenses through Nrf2 pathway activation. SERPINA1 deficiency results in increased oxidative stress markers in neural tissues. [4]
Proteostasis Regulation: As a serpin, A1AT interacts with the protein folding machinery and can influence aggregate formation. In vitro studies demonstrate that A1AT can modify amyloid-beta aggregation kinetics and tau pathology. [5]
Immunomodulation: A1AT modulates T-cell activation and promotes regulatory B-cell function. These effects have therapeutic implications for autoimmune components of neurodegeneration. [6]
Within the central nervous system, alpha-1 antitrypsin is expressed at low basal levels but is upregulated during neuroinflammation. Astrocytes constitute the primary source of CNS-derived A1AT, with microglia producing the protein in response to inflammatory stimuli. Cerebrospinal fluid (CSF) concentrations of A1AT are approximately 1/100th of plasma levels but increase proportionally with systemic inflammation. Importantly, the blood-brain barrier restricts A1AT transit under normal conditions, though neuroinflammation may increase permeability.
Multiple lines of evidence implicate SERPINA1 variants and A1AT levels in AD pathogenesis:
Genetic Association: Genome-wide association studies (GWAS) have identified SERPINA1 polymorphisms associated with altered AD risk. The PiZ allele (E342K) and PiS allele (E264V) variants demonstrate variable effects on disease risk across populations. [7]
Aβ Modulation: A1AT directly interacts with amyloid-beta (Aβ) peptides, inhibiting fibril formation and promoting non-amyloidogenic aggregation. CSF A1AT levels correlate with Aβ42 levels, suggesting a role in amyloid clearance.
Neuroinflammation: Elevated A1AT levels in AD brains correlate with microglial activation markers. The protein's anti-inflammatory properties suggest a compensatory role in limiting neuroinflammation, though dysregulated expression may contribute to disease progression. [8]
Tau Pathology: Emerging evidence indicates A1AT can interact with hyperphosphorylated tau, potentially influencing neurofibrillary tangle formation. Animal models demonstrate that SERPINA1 deficiency exacerbates tau pathology.
In PD, SERPINA1 demonstrates complex relationships with alpha-synuclein pathology:
Alpha-Synuclein Interaction: A1AT binds to alpha-synuclein and inhibits its aggregation in vitro. This suggests a potential protective role in Lewy body formation.
Microglial Activation: PD patients show elevated CSF A1AT levels, correlating with disease severity. The protein appears to modulate microglial activation in response to alpha-synuclein pathology. [9]
Oxidative Stress: Given the central role of oxidative stress in PD pathogenesis, A1AT's antioxidant properties may be particularly relevant. SERPINA1 polymorphisms associated with reduced protein function may increase PD risk.
Neuroprotection: Exogenous A1AT administration protects dopaminergic neurons in toxin-based PD models, supporting a neuroprotective role.
SERPINA1 variants influence ALS susceptibility and progression:
Genetic Studies: Multiple studies have identified SERPINA1 polymorphisms as modifiers of ALS age of onset and survival. The PiZ allele shows protective effects in some populations. [10]
Neuroinflammation: A1AT's anti-inflammatory properties are relevant to the prominent neuroinflammation observed in ALS. The protein reduces motor neuron toxicity from activated microglia.
Protein Aggregation: Given the role of TDP-43 aggregation in ALS, A1AT's chaperone-like properties may influence protein homeostasis.
Over 100 SERPINA1 variants have been described, with the most clinically significant being:
| Variant | Designation | Effect | Clinical Relevance |
|---|---|---|---|
| E342K (Glu342Lys) | PiZ | Severe deficiency | Emphysema, liver disease |
| E264V (Glu264Val) | PiS | Moderate deficiency | Liver disease risk |
| M1 Val213 | M1 | Normal function | Common polymorphism |
| R39C (Arg39Cys) | PiP | Deficiency | Emphysema |
The PiZ (Z) allele, present in approximately 2-4% of individuals of European descent, causes dramatic reductions in circulating A1AT due to protein misfolding and polymerization. Individuals with this variant demonstrate increased susceptibility to emphysema and liver disease, with emerging evidence for neurological complications.
Alpha-1 antitrypsin augmentation therapy (AAT therapy), currently approved for pulmonary emphysema, has potential applications in neurodegeneration:
Development of SERPINA1 expression enhancers represents an alternative strategy:
Understanding SERPINA1's roles in neurodegeneration identifies multiple therapeutic targets:
Several rodent models inform SERPINA1 function in neurodegeneration:
Alpha-1 antitrypsin possesses biomarker characteristics for neurodegeneration:
Key unanswered questions include:
Stolk et al. SERPINA1 in COPD. 2019. ↩︎
Lomas et al. Alpha-1 antitrypsin polymerization. 2008. ↩︎
Golder et al. Alpha-1 antitrypsin and neuroinflammation. 2020. ↩︎
Butters et al. SERPINA1 deficiency and oxidative stress. 2019. ↩︎
Hernandez-Zimbron et al. Alpha-1 antitrypsin and amyloid aggregation. 2018. ↩︎
Popa et al. Alpha-1 antitrypsin modulates microglial activation. 2021. ↩︎
Zhang et al. SERPINA1 variants and Alzheimer's disease risk. 2019. ↩︎
Mueller et al. SERPINA1 in tauopathies. 2019. ↩︎
Marchi et al. Alpha-1 antitrypsin in Parkinson's disease. 2021. ↩︎
Galli et al. SERPINA1 polymorphisms and ALS. 2022. ↩︎